|
|
||||||||
Transfection into a Rodent Tumor Cell Line Increases Intratumoral Dendritic Cell Infiltration but Enhances (Facilitates) Tumor Growth and Decreases Immunogenicity1


* Molecular Medicine Program and Department of Immunology, Mayo Clinic, Rochester, MN 55905; and
Institut National de la Santé et de la Recherché Médicale Unité 517, Faculty of Medicine, Dijon, France
Dendritic cells are powerful APCs for activation of specific antitumor T lymphocytes. To present tumor Ags efficiently, they have first to migrate to the tumor site, engulf Ag, and then process them. To attract immature DCs to the tumor site, we transfected tumor cells with MIP-3
which is strongly chemotactic for DCs. Surprisingly, MIP-3
-transfected tumor cells grew faster than the mock-transfected tumor cells. Histological analysis and tumor dissociation confirmed that the MIP-3
-transfected tumors contain three to four times more DCs than mock-transfected tumors. FACS analysis of the intratumor DCs showed that they were predominantly immature. Functional analysis showed that the alloreactivity mediated by these infiltrating MIP-3
-transfected tumor DCs is strongly reduced. In conclusion, MIP-3
is an efficient chemokine for attracting DCs in vivo, but the high density of DCs in the tumor site injection is not a sufficient condition to induce an immune response. Furthermore, this attraction of immature DCs may always have an adverse effect by inducing a tolerance to the tumor cells.
This article has been cited by other articles:
![]() |
A. Nicolas, D. Cathelin, N. Larmonier, J. Fraszczak, P.-E. Puig, A. Bouchot, A. Bateman, E. Solary, and B. Bonnotte Dendritic Cells Trigger Tumor Cell Death by a Nitric Oxide-Dependent Mechanism J. Immunol., July 15, 2007; 179(2): 812 - 818. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Bergeron, F. El Hage, M. Kambouchner, D. Lecossier, and A. Tazi Characterisation of dendritic cell subsets in lung cancer micro-environments Eur. Respir. J., December 1, 2006; 28(6): 1170 - 1177. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |